$184 Million is the total value of COMMODORE CAPITAL LP's 28 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CCCC | New | C4 THERAPEUTICS INC | $15,939,000 | – | 481,094 | +100.0% | 8.67% | – |
| New | TRILLIUM THERAPEUTICS INC | $12,546,000 | – | 852,871 | +100.0% | 6.82% | – | |
| CNST | New | CONSTELLATION PHARMCETICLS I | $12,203,000 | – | 423,708 | +100.0% | 6.64% | – |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $9,049,000 | – | 532,000 | +100.0% | 4.92% | – |
| KRON | New | KRONOS BIO INC | $8,926,000 | – | 298,839 | +100.0% | 4.85% | – |
| ISEE | New | IVERIC BIO INC | $8,805,000 | – | 1,274,261 | +100.0% | 4.79% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $8,646,000 | – | 1,336,275 | +100.0% | 4.70% | – |
| COGT | New | COGENT BIOSCIENCES INC | $8,535,000 | – | 760,025 | +100.0% | 4.64% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $8,530,000 | – | 1,486,107 | +100.0% | 4.64% | – |
| PMVP | New | PMV PHARMACEUTICALS INC | $7,689,000 | – | 125,000 | +100.0% | 4.18% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $7,346,000 | – | 330,315 | +100.0% | 3.99% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $7,188,000 | – | 467,368 | +100.0% | 3.91% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $7,006,000 | – | 347,500 | +100.0% | 3.81% | – |
| MREO | New | MEREO BIOPHARMA GROUP PLCads | $6,638,000 | – | 1,854,278 | +100.0% | 3.61% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $6,245,000 | – | 356,431 | +100.0% | 3.40% | – |
| VTGN | New | VISTAGEN THERAPEUTICS INC | $6,111,000 | – | 3,150,000 | +100.0% | 3.32% | – |
| RLMD | New | RELMADA THERAPEUTICS INC | $5,727,000 | – | 178,565 | +100.0% | 3.11% | – |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $4,502,000 | – | 97,143 | +100.0% | 2.45% | – |
| KURA | New | KURA ONCOLOGY INC | $4,360,000 | – | 133,503 | +100.0% | 2.37% | – |
| SURF | New | SURFACE ONCOLOGY INC | $4,322,000 | – | 467,796 | +100.0% | 2.35% | – |
| GNCA | New | GENOCEA BIOSCIENCES INC | $4,273,000 | – | 1,765,901 | +100.0% | 2.32% | – |
| MRSN | New | MERSANA THERAPEUTICS INC | $4,226,000 | – | 158,827 | +100.0% | 2.30% | – |
| IMVT | New | IMMUNOVANT INC | $3,870,000 | – | 83,782 | +100.0% | 2.10% | – |
| IVA | New | INVENTIVA SAads | $3,350,000 | – | 231,000 | +100.0% | 1.82% | – |
| BLSA | New | BCLS ACQUISITION CORP | $2,785,000 | – | 250,000 | +100.0% | 1.51% | – |
| CYCC | New | CYCLACEL PHARMACEUTICALS INC | $2,067,000 | – | 264,690 | +100.0% | 1.12% | – |
| MLND | New | MILLENDO THERAPEUTICS INC | $1,980,000 | – | 925,000 | +100.0% | 1.08% | – |
| LSAQ | New | LIFESCI ACQUISITION II CORP | $1,067,000 | – | 100,000 | +100.0% | 0.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.